Cargando…
Influence of graft composition in patients with hematological malignancies undergoing ATG-based haploidentical stem cell transplantation
To determine the influence of graft composition in haplo-HSCT, we summarized the long-term consequences of 251 consecutive transplantations from haploidentical donors. For donor-recipient HLA3/6-matched setting, 125 cases used G-CSF-mobilized BM and PBSCs mixtures, while 126 cases only used G-CSF-mo...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520486/ https://www.ncbi.nlm.nih.gov/pubmed/36189288 http://dx.doi.org/10.3389/fimmu.2022.993419 |
_version_ | 1784799635283378176 |
---|---|
author | Zhang, Ran Lu, Xuan Tang, Liang V. Wang, Huafang Yan, Han You, Yong Zhong, Zhaodong Shi, Wei Xia, Linghui |
author_facet | Zhang, Ran Lu, Xuan Tang, Liang V. Wang, Huafang Yan, Han You, Yong Zhong, Zhaodong Shi, Wei Xia, Linghui |
author_sort | Zhang, Ran |
collection | PubMed |
description | To determine the influence of graft composition in haplo-HSCT, we summarized the long-term consequences of 251 consecutive transplantations from haploidentical donors. For donor-recipient HLA3/6-matched setting, 125 cases used G-CSF-mobilized BM and PBSCs mixtures, while 126 cases only used G-CSF-mobilized PBSCs in HLA4/6-matched transplantation. On the one hand, we wanted to explore the effect of harvests (CD34+ cells and TNCs dosages) on transplantation outcome in the context of haplo-HSCT no matter HLA4/6 or HLA3/6-matched setting. On the other hand, for patients using G-CSF-mobilized BM and PBSCs combination in HLA3/6-matched setting, we attempted to analyze whether TNCs or CD34+ cells from G-CSF-mobilized BM or G-CSF-mobilized PBSCs play the most paramount role on transplantation prognosis. Collectively, patients with hematologic malignancies receiving G-CSF-primed BM and PBSCs harvests had comparable consequences with patients only receiving G-CSF-mobilized PBSCs. Moreover, when divided all patients averagely according to the total amount of transfused nucleated cells, 3-year TRM of the intermediate group (13.06-18.05×10(8)/kg) was only 4.9%, which was remarkably reduced when compared to lower and higher groups with corresponding values 18.3%, 19.6% (P=0.026). The 3-year probabilities of OS and DFS of this intermediate group were 72.6% and 66.5%, which were slightly improved than the lower and higher groups. Most importantly, these data suggest that the transfused nucleated cells from G-CSF-primed BM above than 5.20×10(8)/kg could achieve remarkably lower TRM in haplo-HSCT receiving G-CSF-mobilized BM and PBSCs harvests. These encouraging results suggested that we could improve the efficacy of haplo-HSCT by adjusting the component and relative ratio of transfused graft cells. Nevertheless, the above findings should be confirmed in a randomized prospective comparative research with adequate follow-up. |
format | Online Article Text |
id | pubmed-9520486 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95204862022-09-30 Influence of graft composition in patients with hematological malignancies undergoing ATG-based haploidentical stem cell transplantation Zhang, Ran Lu, Xuan Tang, Liang V. Wang, Huafang Yan, Han You, Yong Zhong, Zhaodong Shi, Wei Xia, Linghui Front Immunol Immunology To determine the influence of graft composition in haplo-HSCT, we summarized the long-term consequences of 251 consecutive transplantations from haploidentical donors. For donor-recipient HLA3/6-matched setting, 125 cases used G-CSF-mobilized BM and PBSCs mixtures, while 126 cases only used G-CSF-mobilized PBSCs in HLA4/6-matched transplantation. On the one hand, we wanted to explore the effect of harvests (CD34+ cells and TNCs dosages) on transplantation outcome in the context of haplo-HSCT no matter HLA4/6 or HLA3/6-matched setting. On the other hand, for patients using G-CSF-mobilized BM and PBSCs combination in HLA3/6-matched setting, we attempted to analyze whether TNCs or CD34+ cells from G-CSF-mobilized BM or G-CSF-mobilized PBSCs play the most paramount role on transplantation prognosis. Collectively, patients with hematologic malignancies receiving G-CSF-primed BM and PBSCs harvests had comparable consequences with patients only receiving G-CSF-mobilized PBSCs. Moreover, when divided all patients averagely according to the total amount of transfused nucleated cells, 3-year TRM of the intermediate group (13.06-18.05×10(8)/kg) was only 4.9%, which was remarkably reduced when compared to lower and higher groups with corresponding values 18.3%, 19.6% (P=0.026). The 3-year probabilities of OS and DFS of this intermediate group were 72.6% and 66.5%, which were slightly improved than the lower and higher groups. Most importantly, these data suggest that the transfused nucleated cells from G-CSF-primed BM above than 5.20×10(8)/kg could achieve remarkably lower TRM in haplo-HSCT receiving G-CSF-mobilized BM and PBSCs harvests. These encouraging results suggested that we could improve the efficacy of haplo-HSCT by adjusting the component and relative ratio of transfused graft cells. Nevertheless, the above findings should be confirmed in a randomized prospective comparative research with adequate follow-up. Frontiers Media S.A. 2022-09-15 /pmc/articles/PMC9520486/ /pubmed/36189288 http://dx.doi.org/10.3389/fimmu.2022.993419 Text en Copyright © 2022 Zhang, Lu, Tang, Wang, Yan, You, Zhong, Shi and Xia https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Zhang, Ran Lu, Xuan Tang, Liang V. Wang, Huafang Yan, Han You, Yong Zhong, Zhaodong Shi, Wei Xia, Linghui Influence of graft composition in patients with hematological malignancies undergoing ATG-based haploidentical stem cell transplantation |
title | Influence of graft composition in patients with hematological malignancies undergoing ATG-based haploidentical stem cell transplantation |
title_full | Influence of graft composition in patients with hematological malignancies undergoing ATG-based haploidentical stem cell transplantation |
title_fullStr | Influence of graft composition in patients with hematological malignancies undergoing ATG-based haploidentical stem cell transplantation |
title_full_unstemmed | Influence of graft composition in patients with hematological malignancies undergoing ATG-based haploidentical stem cell transplantation |
title_short | Influence of graft composition in patients with hematological malignancies undergoing ATG-based haploidentical stem cell transplantation |
title_sort | influence of graft composition in patients with hematological malignancies undergoing atg-based haploidentical stem cell transplantation |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520486/ https://www.ncbi.nlm.nih.gov/pubmed/36189288 http://dx.doi.org/10.3389/fimmu.2022.993419 |
work_keys_str_mv | AT zhangran influenceofgraftcompositioninpatientswithhematologicalmalignanciesundergoingatgbasedhaploidenticalstemcelltransplantation AT luxuan influenceofgraftcompositioninpatientswithhematologicalmalignanciesundergoingatgbasedhaploidenticalstemcelltransplantation AT tangliangv influenceofgraftcompositioninpatientswithhematologicalmalignanciesundergoingatgbasedhaploidenticalstemcelltransplantation AT wanghuafang influenceofgraftcompositioninpatientswithhematologicalmalignanciesundergoingatgbasedhaploidenticalstemcelltransplantation AT yanhan influenceofgraftcompositioninpatientswithhematologicalmalignanciesundergoingatgbasedhaploidenticalstemcelltransplantation AT youyong influenceofgraftcompositioninpatientswithhematologicalmalignanciesundergoingatgbasedhaploidenticalstemcelltransplantation AT zhongzhaodong influenceofgraftcompositioninpatientswithhematologicalmalignanciesundergoingatgbasedhaploidenticalstemcelltransplantation AT shiwei influenceofgraftcompositioninpatientswithhematologicalmalignanciesundergoingatgbasedhaploidenticalstemcelltransplantation AT xialinghui influenceofgraftcompositioninpatientswithhematologicalmalignanciesundergoingatgbasedhaploidenticalstemcelltransplantation |